Ricci Michael J, Medin Jeffrey A, Foley Ronan S
Michael J Ricci, Ronan S Foley, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada.
World J Stem Cells. 2014 Sep 26;6(4):380-90. doi: 10.4252/wjsc.v6.i4.380.
Allogeneic bone marrow transplant is a life-saving procedure for adults and children that have high-risk or relapsed hematological malignancies. Incremental advances in the procedure, as well as expanded sources of donor hematopoietic cell grafts have significantly improved overall rates of success. Yet, the outcomes for patients for whom suitable donors cannot be found remain a significant limitation. These patients may benefit from a hematopoietic cell transplant wherein a relative donor is fully haplotype mismatched. Previously this procedure was limited by graft rejection, lethal graft-versus-host disease, and increased treatment-related toxicity. Recent approaches in haplo-identical transplantation have demonstrated significantly improved outcomes. Based on years of incremental pre-clinical research into this unique form of bone marrow transplant, a range of approaches have now been studied in patients in relatively large phase II trials that will be summarized in this review.
异基因骨髓移植对于患有高危或复发血液系统恶性肿瘤的成人和儿童来说是一种挽救生命的治疗方法。该治疗方法的不断进步以及供体造血细胞移植物来源的扩大显著提高了总体成功率。然而，对于找不到合适供体的患者来说，治疗结果仍然是一个重大限制。这些患者可能会从造血细胞移植中受益，即相对供体完全单倍型不匹配的移植。以前，这种治疗方法受到移植物排斥、致死性移植物抗宿主病以及与治疗相关的毒性增加的限制。近期半相合移植方法已显示出显著改善的治疗结果。基于多年对这种独特形式骨髓移植的渐进性临床前研究，现在已经在相对较大规模的II期试验中对一系列方法进行了患者研究，本综述将对此进行总结。
